For the neurologist community, using ATF3 Promote analysis can improve diagnostic yield when conventional testing with the reduced recovery of DNA synthesis analysis is nonconclusive, especially in the early stages of CS and highly suspected CS cases with neurological and non-neurological phenotypes [1]. The gene discussed is ATF3; the disease is Cowden syndrome 1.